NRAS and neoplasm: Mutations in neurofibromatosis-related protein (NF1), NRAS, and HRAS genes were found in tumours that developed resistance to lorlatinib or ceritinib, and NF1 loss conferred resistance to ALK inhibitors in NB cells [245].